Hologic (HOLX) falls slightly AH after: 1) Announcing a $750M debt offering and $3.05B worth of credit facilities to finance its $3.7B acquisition of Gen-Probe (GPRO). 2) Stating the Gen-Probe acquisition is on track to close around August 1. 3) Pre-announcing FQ3 (ended in June) revenue of $470M and EPS of $0.34-$0.35, which compares with a consensus of $477.5M and $0.34. 4) Reaffirming its FY12 guidance.
Hologic (HOLX) -9.8% following news it's to pay ~$3.7B for Gen-Probe (GPRO), which skies 18.%. While Piper Jaffray's Bill Quirk says that "strategically, this makes all the sense in the world," Dougherty's Junaid Husain is very cautious. Because Gen-Probe is mature, "I am just not sure where they are going to get the accelerated growth."
Hologic (HOLX) agrees to acquire Gen-Probe (GPRO) for ~$3.7B in cash, in the pairing of two smidcap healthcare diagnostics companies. GPRO investors will receive $82.75/share, ~20% above its April 27 closing price. GPRO’s molecular diagnostic products include tests for chlamydia and gonorrhea, as well as human papillomavirus. GPRO +19.3%, HOLX +4.8% premarket.
TPG's acquisition of Immucor (BLUD +30%) fails to spur comparables Bio-Rad Laboratories (BIO -0.7%) and Gen-Probe (GPRO -1.1%). Takeout multiples were below current diagnostics multiples, Leerink notes, and the P-E buyout likely means there was little interest in BLUD from strategic acquirers.
Lab-equipment company Thermo Fisher (TMO) is a leading contender to buy privately owned Swedish allergy testing firm Phadia in a deal that could be worth up to $3B, sources said. A purchase of Phadia could weaken Thermo's interest in Gen-Probe (GPRO).
Gen-Probe (GPRO +13.8%), a maker of tests for AIDS and the West Nile virus, has hired Morgan Stanley to seek a buyer for the company, reports say, with initial bids due in the next couple of weeks. Possible bidders include Novartis (NVS), Thermo Fisher (TMO), Danaher (DHR) and Life Technologies (LIFE).